-
Aspirin therapy, as compared with placebo, significantly reduced the rate of major vascular events with improved net clinical benefit and also reduced the rate of recurrent venous thromboembolism.
-
Disproportionately longer time was allocated to ICU patients discussed early in attending physician handoff sessions, regardless of complexity or severity of illness.
-
-
Aspirin use and AMD risk; using NSAIDs and antihypertensive agents; and FDA actions.
-
Zoledronic Acid Treatment of Osteoporosis in Men; Relapsing Lyme Disease: Fact or Fiction?; Hypertension and Gout
-
Sedentary time is associated with an increased risk of diabetes, cardiovascular disease, and cardiovascular and all-cause mortality.
-
This study does not support the hypothesis that high calcium intake increases coronary artery calcification
-
A randomized, controlled trial showed that moderate doses of simvastatin or pravastatin resulted in reduced energy or exertional fatigue in up to 40% of patients, especially in women.
-
The FDA has approved a new drug with a novel mechanism of action for the treatment of rheumatoid arthritis in patients intolerant to or who have had inadequate response to methotrexate. Tofacifinib is an oral Janus kinase (JAK) inhibitor and is marketed by Pfizer as Xeljanz.
-
In this small pilot study of patients who sought help for insomnia, most of the awakenings were actually caused by sleep-disordered breathing.